Bahram Valamehr

3.3k total citations · 1 hit paper
84 papers, 1.9k citations indexed

About

Bahram Valamehr is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Bahram Valamehr has authored 84 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Oncology, 46 papers in Immunology and 38 papers in Molecular Biology. Recurrent topics in Bahram Valamehr's work include CAR-T cell therapy research (69 papers), Immune Cell Function and Interaction (44 papers) and CRISPR and Genetic Engineering (24 papers). Bahram Valamehr is often cited by papers focused on CAR-T cell therapy research (69 papers), Immune Cell Function and Interaction (44 papers) and CRISPR and Genetic Engineering (24 papers). Bahram Valamehr collaborates with scholars based in United States, Sweden and Norway. Bahram Valamehr's co-authors include Ramzey Abujarour, Dan S. Kaufman, Ryan Bjordahl, Tom Tong Lee, Peter Flynn, Jeffrey S. Miller, David Robbins, Chih‐Ming Ho, Hong Wu and Thuy Le and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Nature Communications.

In The Last Decade

Bahram Valamehr

81 papers receiving 1.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial

2025 42 citations Veronika Bachanová, Krish Patel et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bahram Valamehr United States	24	982	928	799	430	169	84	1.9k
Robert C. Sterner United States	6	1.3k 1.3×	616 0.7×	746 0.9×	451 1.0×	310 1.8×	12	1.9k
Rosalie M. Sterner United States	11	1.4k 1.4×	676 0.7×	805 1.0×	492 1.1×	342 2.0×	22	2.1k
Bizhi Shi China	28	1.7k 1.7×	914 1.0×	1.0k 1.3×	460 1.1×	305 1.8×	53	2.6k
Clare Y. Slaney Australia	23	1.8k 1.9×	761 0.8×	1.2k 1.6×	434 1.0×	304 1.8×	38	2.6k
H. Michael Shepard United States	18	1.8k 1.8×	1.1k 1.2×	561 0.7×	383 0.9×	168 1.0×	40	2.9k
Whitney L. Gladney United States	14	1.8k 1.9×	584 0.6×	1.2k 1.5×	415 1.0×	261 1.5×	24	2.4k
Amer Najjar United States	18	1000 1.0×	517 0.6×	413 0.5×	377 0.9×	276 1.6×	29	1.6k
Hong-Fen Guo United States	25	1.1k 1.1×	783 0.8×	608 0.8×	203 0.5×	240 1.4×	50	2.0k
Vicki Fellowes United States	13	1.0k 1.0×	566 0.6×	510 0.6×	356 0.8×	305 1.8×	29	1.5k

Countries citing papers authored by Bahram Valamehr

Since Specialization

Citations

This map shows the geographic impact of Bahram Valamehr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bahram Valamehr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bahram Valamehr more than expected).

Fields of papers citing papers by Bahram Valamehr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bahram Valamehr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bahram Valamehr. The network helps show where Bahram Valamehr may publish in the future.

Co-authorship network of co-authors of Bahram Valamehr

This figure shows the co-authorship network connecting the top 25 collaborators of Bahram Valamehr. A scholar is included among the top collaborators of Bahram Valamehr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bahram Valamehr. Bahram Valamehr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Strati, Paolo, Januario E. Castro, Aaron M. Goodman, et al.. (2025). Off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy in relapsed or refractory B-cell lymphoma: a multicentre, open-label, phase 1 study. The Lancet Haematology. 12(7). e505–e515. 2 indexed citations

Mahmood, Sajid, et al.. (2025). FT538, iPSC‐derived NK cells, enhance AML cell killing when combined with chemotherapy. Journal of Cellular and Molecular Medicine. 29(1). e70169–e70169. 1 indexed citations

Hancock, Bryan, Brian Groff, Yijia Pan, et al.. (2024). Abstract 3618: High-avidity BCMA CAR and high-affinity, non-cleavable CD16 Fc receptor incorporated in off-the-shelf CAR T cells promote multi-antigen targeting and durable anti-tumor cytotoxicity in the treatment of multiple myeloma. Cancer Research. 84(6_Supplement). 3618–3618. 1 indexed citations

Mahmood, Sajid, et al.. (2023). FT538, iPSC-Derived NK Cells Are Potent Inducers of Apoptosis in AML Cells and Their Effect Is Synergistic in Combination with Approved Therapeutic Strategies. Blood. 142(Supplement 1). 4817–4817. 1 indexed citations

Snyder, Kristin M., Zachary Davis, Martin Hosking, et al.. (2023). iPSC-derived natural killer cells expressing the FcγR fusion CD64/16A can be armed with antibodies for multitumor antigen targeting. Journal for ImmunoTherapy of Cancer. 11(12). e007280–e007280. 13 indexed citations

Drake, Charles G., Alex Garcia, Chia‐Wei Chang, et al.. (2022). 326 Off-the-shelf iPSC-derived CAR-T cells targeting KLK2 demonstrate prolonged tumor control and survival in xenograft models of prostate cancer. Regular and Young Investigator Award Abstracts. A343–A343. 2 indexed citations

Mehta, Amitkumar, Umar Farooq, Andy Chen, et al.. (2022). Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies. Blood. 140(Supplement 1). 4577–4578. 34 indexed citations

Mbofung, Rina M., Yijia Pan, Brian Groff, et al.. (2021). Off-the-Shelf, iPSC-Derived CAR-NK Cells Multiplexed-Engineered for the Avoidance of Allogeneic Host Immune Cell Rejection. Blood. 138(Supplement 1). 2795–2795. 2 indexed citations

Mahmood, Sajid, Yijia Pan, Bryan Hancock, et al.. (2021). Dual Chimeric Antigen Receptor Approach Combining Novel Tumor Targeting Strategies Circumvents Antigen Escape in Multiple Myeloma. Blood. 138(Supplement 1). 1718–1718. 9 indexed citations

10.

Chiu, Emily, Martin Felices, Frank Cichocki, et al.. (2021). Anti-NKG2C/IL-15/anti-CD33 killer engager directs primary and iPSC-derived NKG2C+ NK cells to target myeloid leukemia. Molecular Therapy. 29(12). 3410–3421. 35 indexed citations

11.

Goodridge, Jode, Ryan Bjordahl, Sajid Mahmood, et al.. (2020). FT576: Multi-Specific Off-the-Shelf CAR-NK Cell Therapy Engineered for Enhanced Persistence, Avoidance of Self-Fratricide and Optimized Mab Combination Therapy to Prevent Antigenic Escape and Elicit a Deep and Durable Response in Multiple Myeloma. Blood. 136(Supplement 1). 4–5. 34 indexed citations

12.

Hong, David S., et al.. (2020). 380 Preliminary results of an ongoing phase I trial of FT500, a first-in-class, off-the-shelf, induced pluripotent stem cell (iPSC) derived natural killer (NK) cell therapy in advanced solid tumors. SHILAP Revista de lepidopterología. A231.2–A232. 23 indexed citations

13.

Bjordahl, Ryan, Zhu Huang, Paul Rogers, et al.. (2019). Abstract 3191: FT516, an off-the-shelf engineered NK cell therapeutic product for universal anti-tumor targeting strategy in combination with monoclonal antibodies. Cancer Research. 79(13_Supplement). 3191–3191. 1 indexed citations

14.

Huang, Zhu, Ryan Bjordahl, Svetlana Gaidarova, et al.. (2017). Genetically Engineered Pluripotent Cell-Derived Natural Killer Cell Therapy Provides Enhanced Antibody Dependent Cellular Cytotoxicity Against Hematologic Malignancies and Solid Tumors in Combination with Monoclonal Antibody Therapy. Blood. 130. 4452–4452. 3 indexed citations

15.

Hermanson, David, Branden S. Moriarity, Ryan Bjordahl, et al.. (2017). Engineering Human Induced Pluripotent Stem Cells with Novel Chimeric Antigen Receptors to Generate Natural Killer (NK) Cell Cancer Immunotherapies with Targeted Anti-Tumor Activity. Blood. 130. 1905–1905. 1 indexed citations

16.

Clarke, Raedun, Chia‐Wei Chang, Tom Lee, et al.. (2017). Generation of Clonal Antigen Specific CD8αβ+ Cytotoxic T Lymphocytes from Renewable Pluripotent Stem Cells for Off-the-Shelf T Cell Therapeutics. Blood. 130. 163–163. 1 indexed citations

17.

Bjordahl, Ryan, Raedun Clarke, Svetlana Gaidarova, et al.. (2017). Multi-Functional Genetic Engineering of Pluripotent Cell Lines for Universal Off-the-Shelf Natural Killer Cell Cancer Immunotherapy. Blood. 130. 3187–3187. 1 indexed citations

18.

Abujarour, Ramzey & Bahram Valamehr. (2015). Generation of skeletal muscle cells from pluripotent stem cells: advances and challenges. Frontiers in Cell and Developmental Biology. 3. 29–29. 17 indexed citations

19.

Valamehr, Bahram, Megan Robinson, Ramzey Abujarour, et al.. (2014). Platform for Induction and Maintenance of Transgene-free hiPSCs Resembling Ground State Pluripotent Stem Cells. Stem Cell Reports. 2(3). 366–381. 138 indexed citations

20.

Tsutsui, Hideaki, et al.. (2010). Efficient Dielectrophoretic Patterning of Embryonic Stem Cells in Energy Landscapes Defined by Hydrogel Geometries. Annals of Biomedical Engineering. 38(12). 3777–3788. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact